Schmitt, Jochen and Spuls, Phyllis and Boers, Maarten and Thomas, Kim and Chalmers, Joanne and Roekevisch, Evelien and Schram, Mandy and Allsopp, Richard and Aoki, Valeria and Apfelbacher, Christian and Bruijnzeel-Koomen, Carla and Bruin-Weller, Marjolein and Charman, Carolyn and Cohen, Arnon and Dohil, Magdalene and Flohr, Carsten and Furue, Masutaka and Gieler, Uwe and Hooft, Lotty and Humphreys, Rosemary and Ishii, Henrique Akira and Katayama, Ichiro and Kouwenhoven, Willem and Langan, Sinead and Lewis-Jones, Sue and Merhand, Stephanie and Murota, Hiroyuki and Murrell, Dedee F. and Nankervis, Helen and Ohya, Yukihiro and Oranje, Arnold and Otsuka, Hiromi and Paul, Carle and Rosenbluth, Yael and Saeki, Hidehisa and Schuttelaar, Marie-Louise and Stalder, Jean-Francois and Svensson, Ake and Takaoka, Roberto and Wahlgren, Carl-Fredrik and Weidinger, Stephan and Wollenberg, Andreas and Williams, Hywel (2012) Towards global consensus on outcome measures for atopic eczema research: results of the HOME II meeting. ALLERGY, 67 (9). pp. 1111-1117. ISSN 0105-4538,
Full text not available from this repository. (Request a copy)Abstract
The use of nonstandardized and inadequately validated outcome measures in atopic eczema trials is a major obstacle to practising evidence-based dermatology. The Harmonising Outcome Measures for Eczema (HOME) initiative is an international multiprofessional group dedicated to atopic eczema outcomes research. In June 2011, the HOME initiative conducted a consensus study involving 43 individuals from 10 countries, representing different stakeholders (patients, clinicians, methodologists, pharmaceutical industry) to determine core outcome domains for atopic eczema trials, to define quality criteria for atopic eczema outcome measures and to prioritize topics for atopic eczema outcomes research. Delegates were given evidence-based information, followed by structured group discussion and anonymous consensus voting. Consensus was achieved to include clinical signs, symptoms, long-term control of flares and quality of life into the core set of outcome domains for atopic eczema trials. The HOME initiative strongly recommends including and reporting these core outcome domains as primary or secondary endpoints in all future atopic eczema trials. Measures of these core outcome domains need to be valid, sensitive to change and feasible. Prioritized topics of the HOME initiative are the identification/development of the most appropriate instruments for the four core outcome domains. HOME is open to anyone with an interest in atopic eczema outcomes research.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | ARTHRITIS CLINICAL-TRIALS; DISEASE-ACTIVITY; SEVERITY SCORE; DERMATITIS; OMERACT; TOOL; RHEUMATOLOGY; CHILDREN; EFFICACY; PATIENT; atopic dermatitis; consensus study; measurement; outcome domain; study endpoint |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Institut für Epidemiologie und Präventivmedizin |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 06 May 2020 09:53 |
| Last Modified: | 06 May 2020 09:53 |
| URI: | https://pred.uni-regensburg.de/id/eprint/18242 |
Actions (login required)
 |
View Item |
